Printer Friendly
The Free Library
14,503,364 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Old cure may offer new malaria option.


An herbal-tea remedy for malaria contains a component that may form the basis of a novel drug against the disease, tests in mice show. The compound, called tazopsine, is derived from the bark of a tree (Strychnopsis thouarsii) found in Madagascar's eastern rain forest.

In lab dishes, tazopsine killed the two common malaria parasites Plasmodium falciparum Plasmodium fal·cip·a·rum
n.
A protozoan that causes falciparum malaria.
 and Plasmodium yoelii Plasmodium achiotense is a parasite of the genus Plasmodium subgenus Vinckeia.

Like all Plasmodium species P. yoelii has both vertebrate and insect hosts. The vertebrate hosts for this parasite are mammals.
. Tests in mice newly infected with P. yoelii showed that tazopsine given orally protected 70 percent of the animals, the researchers report in the December 2006 PLoS Medicine PLoS Medicine is a scientific journal covering the full spectrum of the medical sciences it began operation on October 19, 2004. It was the second journal of the Public Library of Science (PLoS) a non-profit organization which releases scientific content under open access .

But tazopsine proved toxic at high doses, limiting the amount that could be given. To get around that, the researchers broke down tazopsine into seven constituent parts. They found that one, dubbed NCP-tazopsine, killed the parasite as well as the whole compound did.

When the scientists gave a quadrupled dose of NCP-tazopsine to mice heavily infected with P. yoelii, the chemical caused no side effects Side effects

Effects of a proposed project on other parts of the firm.
 and killed all the parasites before they could pass through the animals' livers and infect their bloodstreams.

Although it remains unclear how NCP-tazopsine works, the findings suggest that it might prevent malaria from causing illness in newly infected people, such as travelers, soldiers, or others passing through malarial zones, the researchers say. But before it's given to people, NCP-tazopsine must pass tests in chimpanzees against P.falciparum, the parasite strain that causes the most-severe malaria. The researchers also are planning tests of whether the compound eradicates parasites lying dormant in monkeys' livers, says study coauthor Dominique Mazier, a parasitologist parasitologist

a person skilled in parasitology.
 at Pierre and Marie Curie University It has over 180 laboratories, most of them associated with the Centre national de la recherche scientifique.

It is located on the Jussieu Campus in the Latin Quarter of the 5th arrondissement in Paris.
 in Paris.--N.S.
COPYRIGHT 2007 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:BIOMEDICINE
Publication:Science News
Date:Feb 3, 2007
Words:261
Previous Article:Trade-offs in fibroids treatments.(BIOMEDICINE)
Next Article:Gas tanks could guzzle half of U.S. corn yields.(ENERGY)



Related Articles
Malaria vaccine tests under way.
Extended Life, Eternal Life.(biotechnology conference)(Brief Article)
City announces fund investment.(Brief Article)
Homeland security.(dichlorodiphenyl trichloroethane (DDT) lack of effectiveness)(Brief Article)(Illustration)
And other major diseases. (Halting and Beginning to Reverse the Incidence of Malaria).
Malaria: Poverty, Race, and Public Health in the United States.(Book Review)
The Miraculous Fever-Tree: Malaria and the Quest for a Cure That Changed the World.(Book Review)
CRUCELL/US NAVY SIGN PACT TO TEST ADVAC-BASED VACCINE.
Malaria in Kenya's western highlands.
Stung to death: think tsunamis and terrorism are the world's big problems? Bill Gates knows better.(Bill and Melinda Gates Foundation donates funds...

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles